Furthermore, IL‐17 inhibitors have shown profound therapeutic potential in addressing irAEs, such as intestinal issues, arthropathy and psoriasis, in NSCLC, although their use may potentially promote tumour immune escape.183, 184. This evidence concerns the gene IL17A and non-small cell lung carcinoma.